Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2020;31(4):393-9
The Differential Effect of Antibodies on Radiographic Progression in Rheumatoid Arthritis
Authors Information
1. University College London Medical School, Bloomsbury, London, United Kingdom
2. Rheumatology Department, Luton & Dunstable University Hospital NHSFT, Luton, United Kingdom

Amal Minocha, Muhammad Nisar
References
  1. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med 2019 Jun 28;8(7):938.
  2. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012;8:656-64.
  3. Nisar MK, Ostör AJK. Disease remission the goal of therapy in rheumatoid arthritis. Practitioner 2010 Dec;254:17–21, 2.
  4. Sokka T. Healing of erosions in rheumatoid arthritis. Ann Rheum Dis 2000;59:647-9.
  5. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 2009;68:1184-91.
  6. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G,  et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2006;46:342-9.
  7. Nisar MK. Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use. Clin Rheumatol 2019;38:1555-60.
  8. Nisar MK. Early arthritis clinic is effective for rheumatoid and psoriatic arthritides. Rheumatol Int 2019;39:657-62.
  9. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther 2017;19:68.
  10. Lee DM. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Annals of the Rheumatic Diseases 2003;62:870-4.
  11. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis: Anti-CCP Antibody and IgA-RF Predict RA. Arthritis Rheum 2003;48:2741-9.
  12. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:677-80.
  13. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2013;72:875-80.
  14. Burns TM, Calin A. The hand radiograph as a diagnostic discriminant between seropositive and seronegative “rheumatoid arthritis”: a controlled study. Ann Rheum Dis 1983;42:605-12.
  15. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
  16. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122:1791-802.
  17. Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA Rheumatoid Factors Purified from Rheumatoid Arthritis Sera Boost the Fc Receptor– and Complement-Dependent Effector Functions of the Disease-Specific Anti–Citrullinated Protein Autoantibodies. J Immunol 2015;194:3664-74.
  18. Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, et al. Rheumatoid Factor as a Potentiator of Anti-Citrullinated Protein Antibody-Mediated Inflammation in Rheumatoid Arthritis: Interaction Between RF and ACPAs in RA. Arthritis Rheumatol 2014;66:813-21.
  19. van Steenbergen HW, Ajeganova S, Forslind K, Svensson B, van der Helm-van Mil AH. The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis. Ann Rheum Dis 2015;74:e3.
  20. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 2015;74:2151-6.
  21. McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001 Sep;60(9):859-68.
  22. Boeters DM, Nieuwenhuis WP, van Steenbergen HW, Reijnierse M, Landewé RBM, van der Helm-van Mil AHM. Are MRI-detected erosions specific for RA? A large explorative cross-sectional study. Ann Rheum Dis 2018;77:861.